ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tecotabart vedotin

Also written as “LM-302” and “LM-302 Injection”.

In Sino Biopharmaceutical’s pipeline, Claudin18.2 ADC. Its studies are mostly in Adenocarcinoma, led by 2 companies.

Drug pageTecotabart vedotin: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 15, 20246 company-led studies, 3 open or runningNext primary completion: Oct 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceuticalits history only53 open or runningphase 3since Mar 15, 2024Dec 5, 2021Oct 2028phase 3 · NCT07385703
Bristol-Myers Squibb10 open or runningphase 1since Jul 27, 2021Jul 27, 2021none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as LM-302, phase 3, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT05001516 · 17 enrolled · United States
  2. Feb 29, 2024Named tecotabart vedotinINNProposed as its International Nonproprietary Name in WHO's List 130 · before, LM-302

TargetBeta

“Claudin18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

The one study Bristol-Myers Squibb leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05001516Advanced Solid Tumor · United States1CompletedJan 4, 202417

How it is read

Names in the registry

  • “LM-302”, 5 entries
  • “LM-302 Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.